TABLE 2.
Vaginal pH pre- and postapplication of 1%, 3%, and 5% SPL7013 gels and placebo gel
| Formulation | pHa
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1
|
Day 2
|
Day 3
|
Day 4
|
Day 5 | Day 8 | |||||
| T-0 | T-30 | T-0 | T-30 | T-0 | T-30 | T-0 | T-30 | |||
| 1% SPL7013 (pH 4.5) | 6.6 ± 0.9 | 4.7 ± 0.3b | 5.8 ± 0.9 | 4.8 ± 0.3b | 5.5 ± 0.8 | 4.7 ± 0.3 | 6.2 ± 1.2 | 4.8 ± 0.4b | 5.5 ± 0.6 | 6.6 ± 0.6 |
| 3% SPL7013 (pH 4.5) | 6.8 ± 1.1 | 5.0 ± 0.5b | 6.0 ± 0.9 | 4.9 ± 0.4b | 5.8 ± 1.0 | 4.8 ± 0.3 | 5.3 ± 0.9 | 4.8 ± 0.3 | 5.3 ± 1.0 | 6.3 ± 0.7 |
| 5% SPL7013 (pH 4.5) | 6.4 ± 1.2 | 4.8 ± 0.3b | 5.7 ± 1.0 | 4.7 ± 0.3b | 5.7 ± 0.9 | 4.6 ± 0.2b | 6.0 ± 1.1 | 4.5 ± 0.0b | 5.8 ± 0.7 | 6.6 ± 0.7 |
| Placebo gel (pH 4.8) | 6.2 ± 0.8 | 5.1 ± 0.8 | 5.4 ± 0.5 | 4.8 ± 0.3 | 5.3 ± 0.6 | 4.8 ± 0.3 | 5.3 ± 0.7 | 4.9 ± 0.3 | 5.1 ± 0.4 | 6.0 ± 1.1 |
a
Data are presented as means ± standard deviations. T-0, immediately before product application; T-30, 30 min after product application.
b
P < 0.05 (Wilcoxon signed-rank test by comparison of the data for 30 min after product application with those for immediately before product application).